Those Who Invested in Exelixis (NASDAQ:EXEL) Three Years Ago Are up 127%
RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
FDA to Review Exelixis' Application to Expand Use of Cancer Drug
Exelixis Says US FDA Will Review Supplemental NDA for Prospective Treatment for Pancreatic Tumors in March
Exelixis Provides Regulatory Update Related To Supplemental New Drug Application For Cabozantinib; Alliance For Clinical Trials In Oncology Independent Data And Safety Monitoring Board Recommends Trial Enrollment To Be Stopped
Express News | Exelixis Inc - FDA to Discuss Exelixis' Snda for Cabometyx in March 2025
Express News | Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (Cabometyx®) for the Treatment of Patients With Previously Treated Advanced Neuroendocrine Tumors
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX) for the Treatment of Patients With Previously Treated Advanced Neuroendocrine Tumors
Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?
Exelixis Insider Sold Shares Worth $3,394,510, According to a Recent SEC Filing
Exelixis(EXEL.US) Officer Sells US$3.39 Million in Common Stock
$Exelixis(EXEL.US)$ Officer Aftab Dana sold 96,986 shares of common stock on Nov 5, 2024 at an average price of $35 for a total value of $3.39 million.Source: Announcement What is statement of
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
Form 144 | Exelixis(EXEL.US) Officer Proposes to Sell 3.39 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 5, $Exelixis(EXEL.US)$ Officer DANA T AFTAB intends to sell 96,986 shares of its common stock on Nov 5, with a total market value of approximately $3.39 million. DANA T
Here Is Why Growth Investors Should Buy Exelixis (EXEL) Now
Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?
Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
Earnings Call: Exelixis Reports Solid Growth, Raises 2024 Revenue Guidance